{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:59:42Z","timestamp":1793743182176,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WS1940162"],"award-info":[{"award-number":["WS1940162"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21754"],"award-info":[{"award-number":["21754"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21755"],"award-info":[{"award-number":["21755"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1136\/ard-2022-222519","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T18:25:10Z","timestamp":1677003910000},"page":"611-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pre-treatment calprotectin (MRP8\/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-8497","authenticated-orcid":false,"given":"Samantha Louise","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheree","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-3358","authenticated-orcid":false,"given":"Sebastien","family":"Viatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-3926","authenticated-orcid":false,"given":"Anthony G","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7056","authenticated-orcid":false,"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-9344","authenticated-orcid":false,"given":"Darren","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-2527","authenticated-orcid":false,"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222519_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.dld.2014.07.013","article-title":"Faecal calprotectin assay after induction with anti-tumour necrosis factor \u03b1 agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year","volume":"46","author":"Guidi","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1136\/ard-2022-222519_bib2","first-page":"2523","article-title":"Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8\/14 heterodimer in rheumatoid arthritis synovial membrane","volume":"26","author":"Youssef","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X","article-title":"Myeloid-Related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis","volume":"43","author":"Frosch","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222519_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1021\/pr025531w","article-title":"Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid","volume":"1","author":"Uchida","year":"2002","journal-title":"J Proteome Res"},{"key":"10.1136\/ard-2022-222519_bib5","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.11177","article-title":"Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis","volume":"48","author":"Frosch","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222519_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/03009740701874451","article-title":"Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis","volume":"37","author":"Hammer","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib8","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1002\/art.20631","article-title":"Proinflammatory S100 proteins in arthritis and autoimmune disease","volume":"50","author":"Foell","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222519_bib9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-222519_bib10","doi-asserted-by":"crossref","first-page":"R122","DOI":"10.1186\/ar3426","article-title":"Decreases in serum levels of S100A8\/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis","volume":"13","author":"Andr\u00e9s Cerezo","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-016-1201-0","article-title":"Calprotectin (S100A8\/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis","volume":"19","author":"Nordal","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib12","doi-asserted-by":"crossref","first-page":"R178","DOI":"10.1186\/ar3503","article-title":"The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab","volume":"13","author":"Hammer","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2006.064741","article-title":"Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis","volume":"66","author":"Hammer","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/ard.62.3.236","article-title":"Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation","volume":"62","author":"Wulffraat","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/03009742.2015.1107128","article-title":"Calprotectin (S100A8\/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab","volume":"45","author":"Nordal","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0152362","article-title":"A personalized approach to biological therapy using prediction of clinical response based on MRP8\/14 serum complex levels in rheumatoid arthritis patients","volume":"11","author":"Nair","year":"2016","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-222519_bib18","first-page":"1467","article-title":"A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein","volume":"52","author":"Moncrieffe","year":"2013","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1136\/ard-2022-222519_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2018-000654","article-title":"Predictive value of serum calprotectin (S100A8\/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis","volume":"4","author":"Tweehuysen","year":"2018","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222519_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3899\/jrheum.150998","article-title":"Myeloid-Related protein 8\/14 levels in rheumatoid arthritis: marker of disease activity and response to methotrexate","volume":"43","author":"Patro","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib22","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/RHU.0000000000001406","article-title":"Role of serum MRP8\/14 in predicting response to methotrexate in children with juvenile idiopathic arthritis","volume":"27","author":"Bagri","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40291-013-0016-9","article-title":"Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort","volume":"17","author":"Garc\u00eda-Arias","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"10.1136\/ard-2022-222519_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00365513.2017.1413591","article-title":"Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate","volume":"78","author":"Nielsen","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1136\/ard-2022-222519_bib25","doi-asserted-by":"crossref","first-page":"e115800","DOI":"10.1371\/journal.pone.0115800","article-title":"Identification of S100A9 as biomarker of responsiveness to the methotrexate\/etanercept combination in rheumatoid arthritis using a proteomic approach","volume":"9","author":"Obry","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-222519_bib26","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/rheumatology\/kez590","article-title":"MRP8\/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis","volume":"59","author":"Barendregt","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-222519_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222519_bib29","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222519_bib31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","article-title":"Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index","volume":"71","author":"Aletaha","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib33","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/kez049","article-title":"Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis","volume":"58","author":"Hensor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-222519_bib34","series-title":"Stata statistical software: release 14","author":"StataCorp","year":"2015"},{"key":"10.1136\/ard-2022-222519_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/03009749109165280","article-title":"The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis","volume":"20","author":"Berntzen","year":"1991","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acr.22249","article-title":"Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis","volume":"66","author":"Cordingley","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-222519_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cca.2021.02.022","article-title":"Circulating calprotectin as biomarker in neutrophil-related inflammation: pre-analytical recommendations and reference values according to sample type","volume":"517","author":"Mylemans","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1136\/ard-2022-222519_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2172-10-52","article-title":"Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays","volume":"10","author":"de Jager","year":"2009","journal-title":"BMC Immunol"},{"key":"10.1136\/ard-2022-222519_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/gut.47.4.506","article-title":"A simple method for assessing intestinal inflammation in Crohn's disease","volume":"47","author":"Tibble","year":"2000","journal-title":"Gut"},{"key":"10.1136\/ard-2022-222519_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2021-001646","article-title":"Serum calprotectin (S100A8\/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis","volume":"7","author":"La","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222519_bib41","first-page":"667","article-title":"Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: A 5 year follow-up study","volume":"60","author":"Ram\u00edrez","year":"2021","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1136\/ard-2022-222519_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-2064-y","article-title":"Circulating calprotectin (S100A8\/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs","volume":"21","author":"De Moel","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222519_bib43","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","article-title":"Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for A risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: A comparative study","volume":"71","author":"Gerss","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222519_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/art.40727","article-title":"Serum S100A8\/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: relationship to maintenance of clinically inactive disease during anti\u2013tumor necrosis factor therapy and occurrence of disease flare after discontinu","volume":"71","author":"Hinze","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222519_bib45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5114\/reum.2020.98431","article-title":"Blood calprotectin in children with juvenile idiopathic arthritis: relationship to flare development after discontinuation of treatment","volume":"58","author":"Boyko","year":"2020","journal-title":"Reumatologia"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:35:51Z","timestamp":1739522151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724084607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003496724084607"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222519","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-treatment calprotectin (MRP8\/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}